Cardiacys Division · Phorcys Pharmaceuticals

Empaphor
SGLT-2 Inhibitor Range

Empagliflozin formulations for Cardio-diabetic Management

Empaphor provides cardio-protective benefits alongside advanced glycemic control.

Designed for patients with established cardiovascular disease and Type 2 diabetes. Explore the entire Empaphor profile below.

View Products Contact Our Team

Clinical Rationale

Type 2 Diabetes + Risk Factors = Cardiovascular Risk

🫀

Hypertension & Abnormal Cholesterol

⚖️

Obesity & High Triglycerides

🏃

Lack of Physical Activity

🩸

Poorly Controlled Blood Sugar

🚬

Smoking

Managing these risk factors with advanced therapies like Empaphor may delay the progression of cardiovascular issues.
Ref: heart.org — Cardiovascular Disease & Diabetes

Product Range

The Empaphor Family Formulation Profiles

Three strategic therapeutic avenues for comprehensive Type 2 Diabetes management

Empaphor 10/25

Generic: Empagliflozin 10 mg / 25 mg
CV Protection

Targeted approach for high-risk cardiac individuals requiring systemic stabilization alongside intensive blood sugar management.

  • Significant HbA1c reduction (−0.7% over Metformin)
  • Proven cardio-protective SGLT-2 benefit
  • Flexible dosing choices under professional supervision

Empaphor M5 · M12.5

Generic: Empagliflozin (5 mg / 12.5 mg) + Metformin 500 mg
Dual Action Combinations

Optimized fixed-dose asset providing synchronous action mechanisms to streamline treatment regimens and adherence patterns.

  • Dual glycemic baseline regulation tracking
  • Two structural titration tiers
  • Simplified daily adherence schedule

Empaphor L

Generic: Empagliflozin 25 mg + Linagliptin 5 mg
Advanced Combination Therapy

For patients requiring aggressive escalation pathways to bridge structural glycaemic deficits comprehensively.

  • Addresses 5 distinct functional defects simultaneously
  • Dual pathway optimization framework
  • Stabilizes systemic renal glucose retention dynamics

Clinical Evidence Baseline

Empaphor Range Therapeutic Performance Metrics

Data profiles indicate sustained structural adjustments to HbA1c curves during comprehensive 24-week evaluation tracks.

−0.70%
HbA1c optimization margin metrics
−0.82%
Comparative dual-arm variations observed
P<0.001
Validated data significance bounds
24 wk
Standard operational evaluation window
Percent Change in HbA1c parameters over standard evaluation window
Active Formulations vs Static Baselines
Control
−0.70%
Monotherapy Paths
Data Subset N=207
Control
−0.82%
Combination Paths
Data Subset N=225
Baseline Control
Empaphor Active Track
*P<0.001

Data references adapted from peer-evaluated international clinical registers.

Empaphor L Mechanism Profile

5 of 8
Pathological Anomalies Managed Concurrently
1
Incretin vector support pathways
2
Insulin dynamic stability profiles
3
Glucagon surge mitigation features
4
Hepatic sugar outpour dampening
5
Renal filtration processing modification

Complementary Biochemical Interventions

Empaphor L targets metabolic issues using a multi-surface platform strategy, resolving multiple biological dysfunctions simultaneously.

Corporate Framework

Cardiacys Division
Phorcys Pharmaceuticals Pvt Ltd

Empaphor is the premier trademarked platform developed under Phorcys Pharmaceuticals Pvt Ltd (Cardiacys Division), delivering specialized care across metropolitan and regional environments within the domestic Indian healthcare ecosystem.

Corporate Connection Channels

🏢

Registrar & Corporate Hub

Door No. 4/502, Gaurav Excellency
Hatkesh Udyog Nagar, Mira Road East
Mumbai, Maharashtra – 401107

🌐

Web Platform Access

www.phorcyspharma.com

✉️

Communication Channels

info@phorcyspharma.com
phorcyspharma@gmail.com

For Licensed Medical Practitioner Access Only. Information provided points to prescription-dependent formulations distributed within the domestic Indian market space. Professional prescription authorization is strictly required.